INCB 3284

Drug Profile

INCB 3284

Alternative Names: INCB3284

Latest Information Update: 28 May 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Incyte Corporation
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Insulin resistance; Rheumatoid arthritis

Most Recent Events

  • 23 Nov 2005 Incyte and Pfizer have entered into an exclusive worldwide agreement for the development, manufacture and marketing of INCB 3284 and other CCR2 antagonists
  • 08 Aug 2005 Phase-II clinical trials in Insulin resistance in USA (PO)
  • 04 May 2005 Phase-II clinical trials in Rheumatoid arthritis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top